Targets › MAGL
2 programs from 2 companies in 4 trials: 3 Phase 2, 1 Phase 1; Neurology, Other; next expected readout Dec 2026.
Open in Phaseline: the race on MAGL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Irafamdastat (BMS-986368, CC-97489) FAAH/MAGL inhibitor | FAAH, MAGL | Phase 2 | Multiple Sclerosis Spasticity; Agitation; Healthy Volunteers | Dec 2026 |
| Alberto Esquenazi | BMS-986368 FAAH/MAGL inhibitor | FAAH, MAGL | Phase 2 | Post-Stroke Spasticity | Jun 2027 |
Post-Stroke Spasticity (1) Multiple Sclerosis Spasticity (1) Agitation (1) Healthy Volunteers (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.